Intermediate-size Patient Population Expanded Access Protocol

Inclusion Criteria:

- ALS diagnosis

- Age 18 -80 years at time of signing informed consent form

- Ineligible for other interventional ALS clinical research participation

- Vital Capacity greater than 35% of predicted capacity for age, height, and sex

- If currently taking standard of care treatment for ALS, must be on stable dose for
at least 30 days prior to taking SPG302.

- Life expectancy of at least 6 months, according to Investigator's judgement

Exclusion Criteria:

- Clinically significant and/or unstable medical condition (other than ALS) that would
pose a risk to the patient

- Known ongoing or clinically uncontrolled cardiac disease

- Clinically significant liver disease

- Clinical significant cognitive impairment or neurological disorder, as determined by
Investigator judgement

- Concomitant use of another investigational medical product for treatment of ALS

- Unable to reliably and regularly swallow whole oral medications on a daily basis